Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intraepithelial Neoplasia Clear all
Completed Phase 1 Interventional

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

NCT02065973
View directory record Official record
Conditions
High-risk HPV Infection and Biopsy-proven CIN1
Interventions
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Biological
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Port Jefferson, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Not applicable Interventional Results available

Activating Collaborative CIS Support Via Targeted Provider Mailing

NCT00873288
View directory record Official record
Conditions
Precancerous Condition
Interventions
Usual care mailing intervention, CIS support mailing intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

NCT03300557
View directory record Official record
Conditions
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 13, 2026, 8:12 AM EDT
Recruiting Phase 1 Interventional

Lopinavir/Ritonavir in PLWH With High-Grade AIN

NCT05334004
View directory record Official record
Conditions
High-Grade Anal Intraepithelial Neoplasia
Interventions
Lopinavir / Ritonavir
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

NCT06159842
View directory record Official record
Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
Aminolevulinic Acid 20% Topical Solution with Blue Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 13, 2026, 8:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of Polarized Light Assisted Colposcopy

NCT01349621
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 13, 2026, 8:12 AM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

NCT02882282
View directory record Official record
Conditions
Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia
Interventions
Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

NCT00703196
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
folic acid, placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Sep 13, 2026, 8:12 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Not applicable Interventional Results available

A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System

NCT01970787
View directory record Official record
Conditions
HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions
Interventions
Radiofrequency Ablation (RFA) using the HALO Ablation System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 13, 2026, 8:12 AM EDT
Completed No phase listed Observational

A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening

NCT01058148
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Human Papillomavirus
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
26 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 13, 2026, 8:12 AM EDT
Recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 3 Interventional

Fenretinide in Treating Patients With Cervical Neoplasia

NCT00003075
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Fenretinide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

NCT05496231
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 26 Years · Female only
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 13, 2026, 8:12 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

NCT01304524
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
VGX 3100, Placebo, CELLECTRA™-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 13, 2026, 8:12 AM EDT
Completed No phase listed Observational

IMproved PRactice Outcomes and Value Excellence in Colposcopy

NCT02185599
View directory record Official record
Conditions
High Grade Cervical Intraepithelial Neoplasia
Interventions
DySIS
Device
Lead sponsor
DySIS Medical Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
7,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
46
States / cities
Scottsdale, Arizona • Gainesville, Florida • Jacksonville, Florida + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 13, 2026, 8:12 AM EDT
Recruiting No phase listed Observational

Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™

NCT05853783
View directory record Official record
Conditions
Mouth Diseases
Interventions
STRATICYTE™ Test
Other
Lead sponsor
Proteocyte Diagnostics Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Loma Linda, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

NCT00550589
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
Drug · Genetic · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 13, 2026, 8:12 AM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 13, 2026, 8:12 AM EDT
Withdrawn Phase 1 Interventional

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

NCT04411134
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 13, 2026, 8:12 AM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 13, 2026, 8:12 AM EDT